Eight Humira biosimilars have been launched, but payer formularies and interchangeability rules decide what dispenses.
|Videos|February 9, 2015
How Will Biosimilars Impact the US?
Raulo Frear, PharmD, general manager of OmedaRx, discusses the ramifications of biosimilars hitting the US market.
Advertisement
Raulo Frear, PharmD, general manager of OmedaRx, discusses the ramifications of biosimilars hitting the US market.
Advertisement
Related to this article
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
A biologic stewardship framework can enhance consistency, safety, and sustainability of biologic use in health systems.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Armored CAR T-Cell Therapy Produces Durable Complete Response in Pediatric Solid Tumors
2
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
3
After 180 Years, Multiple Myeloma Gets a Definition of Cure
4
Not So Rare After All: Pharmacists Weigh In on Diagnosing and Managing ATTR-CM
5